<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="186">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366180</url>
  </required_header>
  <id_info>
    <org_study_id>P054</org_study_id>
    <nct_id>NCT04366180</nct_id>
  </id_info>
  <brief_title>Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers</brief_title>
  <official_title>Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosearch S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosearch S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8
      consumption on the incidence and severity of Covid-19 in health workers exposed to the virus.
      This is a preventive study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SARS CoV-2 infection in healthcare workers</measure>
    <time_frame>8 weeks</time_frame>
    <description>The incidence of SARS CoV-2 infection will be confirmed by PCR or antigen test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospital admissions caused by SARS-CoV-2 infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required hospital admission because of Covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ICU admissions caused by SARS-CoV-2 infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required ICU admission because of Covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pneumonia caused by SARS-CoV-2 infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop pneumonia because of Covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of oxygen support requirement caused by SARS-CoV-2 infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will require oxygen support because of Covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop gastrointestinal symptoms because of Covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with body's temperature &gt; 37.5 ºC</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with body's temperature &gt; 37.5 ºC during the course of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with cough</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with cough during the course of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with fatigue</measure>
    <time_frame>8 weeks</time_frame>
    <description>In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with fatigue during the course of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Use of drugs (dosis and duration of the treatment) for Covid-19 treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group who will receive a daily placebo capsule consisting of maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>The probiotic group will received one capsule with Lactobacillus K8 per day (3x10^9 cfu/day) during 2 months</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>The control group will received one placebo capsule per day during 2 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Persons over 20 years of age.

          2. Active healthcare personnel, who attend patients with COVID-19 disease, including all
             professional categories, medicine, nursing and warders.

          3. Ability to complete surveys.

          4. Signature of informed consent

        Exclusion Criteria:

          1. Person with positive test of COVID-19 confirmed by PCR test or serology

          2. Person with concomitant pathology HIV, transplant, active oncology or other type of
             active immunosuppression

          3. Pregnant women or women with intention to become pregnant in the next 2 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raquel Rodriguez Blanque</last_name>
    <phone>+34 958 023 000</phone>
    <email>raquel.rodriguez.blanque.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Raquel Rodriguez Blanque</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Rodriguez Blanque</last_name>
      <phone>+34 958 023 000</phone>
      <email>raquel.rodriguez.blanque.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Prevention</keyword>
  <keyword>Healthcare workers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

